资料显示，哈尔滨三联药业股份有限公司位于黑龙江省哈尔滨市利民开发区北京路，成立日期1996年6 月21日，上市日期2017年9月22日，公司主营业务涉及化学药品制剂的研发、生产和销售。主营业务收 入构成为：大输液32.00%，冻干粉针剂18.39%，固体制剂17.39%，小容量注射剂14.34%，其他(补 充)10.26%，兽药2.55%，进出口贸易1.82%，原料药1.73%，化妆品0.94%，医疗器械0.43%，功能食品 0.16%。 哈三联所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、抗流感、肝 炎治疗、创新药、宠物经济等。 12月18日，哈三联盘中上涨2.10%，截至13:41，报13.15元/股，成交4103.33万元，换手率1.81%，总市 值41.60亿元。 资金流向方面，主力资金净流入46.33万元，大单买入354.33万元，占比8.64%，卖出308.00万元，占比 7.51%。 哈三联今年以来股价涨36.27%，近5个交易日跌1.79%，近20日跌4.29%，近60日跌4.15%。 今年以来哈三联已经9次登上龙虎榜，最近一次登上龙虎榜为6月3日。 截至12月1 ...

Core Viewpoint - Nocera Biopharma's stock has experienced a significant decline recently, despite a strong year-to-date performance, indicating potential volatility in the market [1][2]. Group 1: Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is primarily engaged in the research, production, and commercialization of biopharmaceuticals, focusing on unmet clinical needs in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [2]. - Nocera Biopharma operates mainly in China and the United States, with a product pipeline that includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723 [2]. Group 2: Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% year-on-year [2]. - The company's stock price has increased by 78.99% year-to-date, but it has seen declines of 7.76% over the last five trading days, 9.06% over the last 20 days, and 18.29% over the last 60 days [1]. Group 3: Shareholder Information - As of September 30, 2025, Nocera Biopharma had 16,500 shareholders, an increase of 8.66% from the previous period [2]. - The top ten circulating shareholders include various funds, with notable changes such as a decrease in holdings by 富国精准医疗灵活配置混合A and new entries like 万家优选 and 平安医疗健康混合A [3].

中国经济网深圳12月18日讯 12月14日，由平安期货、平安证券联合主办的 2026 全球交易者大会暨 中国平安第七届全国期货实盘大赛颁奖典礼，在深圳福田举行。 本次大会，有近500位交易者从全国各地赶来，齐聚在此，只为寻找一束确定的光，全球交易者大 会也一直致力于帮助众多交易者完成一场从孤军奋战到协同进化的深层蜕变。平安期货总经理袁建峰指 出，平安期货始终坚守"以客户为中心"的初心，在市场环境变化中践行有温度的风险管理服务，以专业 服务助力交易者行稳致远，践行为客户创造价值的承诺。 当时代浪潮裹挟速度加快，平安期货也将肩负起风险识别、风险管理、风险应对的责任担当，打造 客户信赖首选的智慧衍生品服务，为居民财富管理与实体经济发展提供更精准、更有力的"金融力量"。 平安基金权益投资基金经理周思聪表示，在第四次科技革命深入演进的背景下，AI、算力、半导 体、创新药等领域迎来关键时刻。其中中国创新药行业在技术周期、政策周期和利率环境的三重支撑下 厚积薄发，2026年整个行业依然存在贝塔行情，且个股的阿尔法行情也将起步。 平安期货研究所所长李晨阳结合海内外政治经济格局变化，指出贵金属长期上行格局未改，同时紧 扣 "反 ...

Core Viewpoint - The stock of Haoyuan Pharmaceutical has experienced a decline of 2.05% on December 18, 2023, despite a year-to-date increase of 100.54% [1] Group 1: Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of small molecule drug discovery, including molecular building blocks and tool compounds [2] - The company's main business revenue composition includes molecular building blocks and tool compounds (68.97%), with product sales contributing 63.42%, raw materials and intermediates 30.46%, and technical services 5.55% [2] - As of September 30, 2023, the number of shareholders is 12,000, a decrease of 6.34% from the previous period, with an average of 17,647 circulating shares per person, an increase of 6.77% [2] Group 2: Financial Performance - For the period from January to September 2023, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, up 65.09% year-on-year [2] - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3] Group 3: Stock Market Activity - On December 18, 2023, Haoyuan Pharmaceutical's stock price was reported at 71.13 yuan per share, with a trading volume of 111 million yuan and a turnover rate of 0.73%, resulting in a total market capitalization of 15.087 billion yuan [1] - The stock has seen a net outflow of 2.4429 million yuan from major funds, with significant buying and selling activities recorded [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with the last occurrence on May 30, 2023, where it recorded a net purchase of 10.336 million yuan [1]

Market Overview - The A-share market showed mixed performance on December 18, with the Shanghai Composite Index turning positive while the ChiNext Index fell nearly 2% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.05 trillion yuan, an increase of 192 billion yuan compared to the previous trading day, with over 3,600 stocks rising [1] Sector Performance - The commercial aerospace and pharmaceutical sectors led the gains, while battery and securities sectors experienced declines [1] - Notable stocks in the commercial aerospace sector included China Satellite (600118), Beimo High-tech (002985), and Tianjian Technology (002977), all of which hit the daily limit [3][5] - The pharmaceutical sector also showed strength, with companies like Huaren Health (301408) and Yingte Group (000411) achieving daily limit gains [6][8] Noteworthy Developments - The Long March 12甲 reusable launch vehicle, developed by the China Aerospace Science and Technology Corporation, is scheduled for its historic first launch in December 2025 [3] - The brain-computer interface and innovative medical device sectors have seen significant breakthroughs, with analysts optimistic about investment opportunities due to supportive policies [8] Individual Stock Highlights - On December 18, China International Capital Corporation (601995) and Dongxing Securities resumed trading with limit-up prices, while Xinda Securities (601059) opened 6.8% higher [9] - Newly listed Yuan Chuang Co., Ltd. (001325) saw its stock price surge over 200% at the opening, closing at 70.99 yuan per share, with a leading market share in rubber track products [9][10] Future Market Outlook - Analysts from Industrial Securities express a positive outlook for the A-share market in 2026, citing limited negative external impacts and favorable trends in AI and liquidity [11] - Key sectors expected to drive growth include AI, new energy, military industry, and innovative pharmaceuticals, with a focus on companies with global competitive advantages [11]

Core Viewpoint - Yuyuan Pharmaceutical experienced a stock price decline of 2.08% on December 18, with a current price of 21.68 CNY per share and a market capitalization of 9.756 billion CNY [1] Financial Performance - For the period from January to September 2025, Yuyuan Pharmaceutical reported a revenue of 1.759 billion CNY, a year-on-year decrease of 41.20%, and a net profit attributable to shareholders of -148 million CNY, a year-on-year decrease of 170.56% [3] - The company has distributed a total of 1.092 billion CNY in dividends since its A-share listing, with 584 million CNY distributed over the past three years [4] Stock Market Activity - Yuyuan Pharmaceutical's stock has increased by 50.45% year-to-date, but has seen a decline of 19.23% over the last five trading days, 3.08% over the last 20 days, and 11.98% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on August 27, where it recorded a net buy of -105 million CNY [1] Shareholder Information - As of September 30, 2025, Yuyuan Pharmaceutical had 10,700 shareholders, a decrease of 8.39% from the previous period, with an average of 42,095 circulating shares per shareholder, an increase of 9.16% [3] - The top ten circulating shareholders include notable funds such as the Fortune Precision Medical Flexible Allocation Mixed A and the E Fund Healthcare Industry Mixed A, with changes in their holdings noted [4] Business Overview - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [2] - The revenue composition includes 55.67% from cardiovascular drugs, 20.88% from anti-infection drugs, and smaller percentages from other categories [2]

12月18日早盘，A股港股市场弱势震荡，医药资产逆市活跃，彰显防御力。 A股市场上，医疗板块延续较强反弹力度，全市场最大医疗ETF（512170）盘中涨超1%上穿年线！民营医院、AI医疗相关成份股涨幅居前，美年健康两连 板，卫宁健康涨超7%。 制药板块个股涨跌分化，中药龙头片仔癀涨超1%，创新药概念股甘李药业、海思科跌1%，全市场唯一药ETF（562050）水面附近盘整。 值得一提的是，昨日，医疗ETF（512170）日K呈现"一阳包两阴"形态，技术面释放"多空转换"信号！今日如能成功收于年线上方，短期趋势有望反转。资 金面上，近期部分资金逢跌吸筹，512170近10日累计吸金超9300万元。 3）创新器械设备：近日先瑞达医疗与全球器械设备龙头公司，美国波士顿科学，签署合作协议。据观察，海外头部药企MNC近期加大了对中国创新器械的 关注，且这一板块整体的景气度和估值水位已经凸显价值区间，类似于去年启动前的港股创新药板块。此外，这一板块是医药信息化和AI应用的直接下 游，有望切实落地生产力的提升。 港股医药今日一枝独秀，截至发稿恒指、恒科指均飘绿，创新药龙头多股上涨，百济神州涨超1%，石药集团涨超3%，创新药含 ...

NO.1 献血年龄拟延长至65周岁献血法修订草案公开征求意见 12月17日，国家卫生健康委发布公告，就献血法（修订草案征求意见稿）面向社会公开征求意见。献血 者年龄从提倡18周岁至55周岁，修订为提倡18周岁至65周岁的公民在符合健康要求的情况下自愿献血。 血站对献血者每次采集全血不得超过400毫升，两次采集全血间隔期从不少于6个月修订为不少于90天。 点评：新的献血草案提高了献血年龄的上限，并且缩短了全血捐献的间隔，有助于改善我国血液供应的 稳定性。 NO.2 同仁堂：未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何股权及投资权益 NO.3 亚虹医药：APL-2401临床试验申请获得国家药品监督管理局批准 12月17日，亚虹医药公告称，公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》， 公司APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展I期临床试验申请获得批准。该款药物为全球同 步研发的1类创新药，审评审批环节仅22个工作日就获得批准，成为全国首批获得此项新政审批通过的 项目之一。 点评：亚虹医药APL-2401的临床试验通过"30日通道"加速落地，体现出政策对创新药的支 ...

Core Viewpoint - The stock price of Yipinhong (300723) has experienced a significant decline following the announcement of the sale of its stake in Arthrosi, which is developing the gout drug AR882. Despite retaining 100% rights to AR882 in China, investors reacted negatively, perceiving the sale as a loss of a beneficial project [2][8][9]. Group 1: Stock Performance - Yipinhong's stock price fell nearly 30% over three trading days following the announcement of the Arthrosi stake sale [5][7]. - On December 17, the stock opened down 1.53% and hit a low of nearly 5% during the day, closing at 33.34 yuan per share, down 0.24% [5][6]. - The stock hit a limit down of 20% on December 15, prompting the company to announce a share buyback plan of 100 to 200 million yuan to stabilize investor confidence [6][7]. Group 2: Transaction Details - Arthrosi is a subsidiary in which Yipinhong holds a 13.45% stake through its wholly-owned subsidiary [6]. - The acquisition agreement with Sobi USA involves a $950 million upfront payment (approximately 6.713 billion yuan) and up to $550 million (approximately 3.887 billion yuan) in milestone payments [5][6]. Group 3: Product Focus - AR882 is a selective urate transporter (URAT1) inhibitor aimed at treating gout and related conditions, currently in critical Phase III clinical trials [8][9]. - Yipinhong retains 100% market rights for AR882 in China and has priority for global supply rights post-transaction [8][9]. Group 4: Financial Performance - Yipinhong is facing significant financial pressure, with projected revenues for 2024 expected to drop by 42.07% to approximately 1.45 billion yuan, resulting in a net loss of about 540 million yuan [11]. - For the first three quarters of this year, the company reported revenues of approximately 814 million yuan, a decline of 34.35%, with a net loss of about 136 million yuan [11]. Group 5: Future Outlook - The company aims to submit 1-2 innovative drug applications annually, focusing on best-in-class or first-in-class products to meet unmet clinical needs [12].

Group 1 - A-shares and Hong Kong stocks experienced a significant rebound, with the Shanghai Composite Index rising by 1.19% and the Hang Seng Index increasing by 0.92% [1] - The largest medical ETF in the market (512170) and the only drug ETF (562050) both rose over 1%, indicating a broad recovery in the medical sector [1] - The medical ETF (512170) showed a strong technical signal with a "bullish engulfing" pattern, suggesting a potential trend reversal [1] Group 2 - The pharmaceutical sector in A-shares also saw a surge, with the drug ETF (562050) rising by 1.19%, driven by contributions from innovative and traditional Chinese medicine stocks [3] - The drug ETF (562050) has approximately 25% weight in traditional Chinese medicine, which helps mitigate the volatility of the overall pharmaceutical index [3] Group 3 - The Hong Kong innovation drug sector is showing signs of recovery, with the Hong Kong innovation drug ETF (520880) successfully closing in the green, attracting "bottom-fishing" funds [5] - The fund size of the Hong Kong innovation drug ETF (520880) reached a new high of 4.172 billion shares, reflecting strong investor interest [5] Group 4 - The A+H pharmaceutical sector has been in a correction phase for three months, and analysts suggest that this may be an opportune time for medium to long-term investments in pharmaceutical assets [8] - Recent positive developments in the pharmaceutical industry include overseas collaborations and increasing demand for CXO services, indicating a favorable outlook for the sector [9] Group 5 - The fund manager of the Hong Kong innovation drug ETF (520880) maintains a balanced allocation strategy, highlighting the potential for recovery in the innovative drug industry and related sectors [10] - New investment tools, such as the Hong Kong medical ETF (159137), are being launched to track the medical innovation theme, covering various core leaders in the medical field [7]